A Randomized, Clinical Study to evaluate the Efficacy and Safety of Safoof-i-Ushba and Roghan-i-Banafsha in Taqashshur al-Jild(Psoriasis)
Phase 2
- Conditions
- Health Condition 1: L408- Other psoriasis
- Registration Number
- CTRI/2023/03/050418
- Lead Sponsor
- ational Research Institute of Unani Medicine for Skin Disorders
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patient clinically stable.
2. Patient with clinically diagnosed Taqashshur al-jild (psoriasis) of
plaque type.
3. Psoriasis area severity index (PASI) >=10%
Exclusion Criteria
1. Participants aged <18and >60years
2. Known cases of significant Pulmonary/Cardiovascular/ Hepato-renal Dysfunction, Malignancy, HIV infection, AIDS, etc.
3. Erythrodermic psoriasis.
4. Pregnancy and Lactation.
5. Patient not willing to attend treatment regularly.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Reduction in Psoriasis Area Severity Index (PASI) <br/ ><br>2. Improvement in Investigators Global Assessment (IGA) <br/ ><br>3. Improvement in Patientâ??s Global Assessment (PGA) on VASTimepoint: 12 weeks
- Secondary Outcome Measures
Name Time Method Systemic Safety AssessmentTimepoint: 12 weeks